- Home
- GSK vs VRTX Comparison
GSK vs VRTX Comparison
Compare GSK & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSK
- VRTX
- Stock Information
- Founded
- GSK 1715
- VRTX 1989
- Country
- GSK United Kingdom
- VRTX United States
- Employees
- GSK N/A
- VRTX N/A
- Industry
- GSK Biotechnology: Pharmaceutical Preparations
- VRTX EDP Services
- Sector
- GSK Health Care
- VRTX Technology
- Exchange
- GSK Nasdaq
- VRTX Nasdaq
- Market Cap
- GSK 81.9B
- VRTX 96.6B
- IPO Year
- GSK N/A
- VRTX 1991
- Fundamental
- Price
- GSK $46.86
- VRTX $425.57
- Analyst Decision
- GSK Buy
- VRTX Buy
- Analyst Count
- GSK 3
- VRTX 26
- Target Price
- GSK N/A
- VRTX $491.78
- AVG Volume (30 Days)
- GSK 5.5M
- VRTX 1.3M
- Earning Date
- GSK 10-29-2025
- VRTX 11-03-2025
- Dividend Yield
- GSK 3.46%
- VRTX N/A
- EPS Growth
- GSK 118.57
- VRTX N/A
- EPS
- GSK 1.79
- VRTX 14.07
- Revenue
- GSK $43,237,357,842.00
- VRTX $11,418,800,000.00
- Revenue This Year
- GSK $5.50
- VRTX $10.93
- Revenue Next Year
- GSK $5.21
- VRTX $9.55
- P/E Ratio
- GSK $12.73
- VRTX $30.25
- Revenue Growth
- GSK 2.73
- VRTX 10.46
- 52 Week Low
- GSK $31.72
- VRTX $362.50
- 52 Week High
- GSK $47.16
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- GSK 72.69
- VRTX 61.34
- Support Level
- GSK $42.89
- VRTX $415.00
- Resistance Level
- GSK $47.16
- VRTX $422.98
- Average True Range (ATR)
- GSK 0.78
- VRTX 8.21
- MACD
- GSK 0.19
- VRTX 0.10
- Stochastic Oscillator
- GSK 93.05
- VRTX 73.67
About GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.